States. At present, there is little information available about their response to therapy.
children, there are few data in adolescents to substantiate the successful control of HIV. Knowledge of the effectiveness of HAART in this population is critical, because ∼50% of all new cases of HIV infection in the United States occur in adolescents and young adults 13-24 years old [7] . Because of unique behavioral characteristics, adolescents may have greater difficulty adhering to complex regimens of HAART [8, 9] , thus negating the positive effect of HAART seen in adults and children. Furthermore, data suggest that adolescents may have a greater thymic capacity than adults. Studies of the peripheral blood of HIV-infected adolescents have demonstrated increased levels of CD8 naive T cells [10, 11] and an increased proliferation of naive cell subsets, as measured by the Ki67 antigen [12] and T cell-receptor excision circle assays [13, 14] , com-pared with reported values in HIV-infected adults [15] [16] [17] [18] [19] . Thus, this population may have greater potential for sustained immune reconstitution during HAART. The Pediatric AIDS Clinical Trials Group (PACTG) 381 study was initiated to determine whether there was a correlation between baseline immunologic status and long-term response to HAART, over the course of 3 years, in adolescents infected via high-risk behaviors. We also sought to describe the short-term virologic and immunologic responses to HAART, estimate the adolescent's ability to adhere to HAART, and determine whether baseline immunologic features were predictive of short-term success. We report the findings from the first 24 weeks of therapy.
SUBJECTS AND METHODS

Study design.
This open-label study of HAART was conducted at 28 PACTG sites in the United States and Puerto Rico. The study was approved by each site's institutional review board. Patients were eligible for participation if they were between 8 and 22 years old, had HIV-1 infection documented by any 2 commercially available HIV-1 diagnostic tests, were antiretroviral naive (except for zidovudine monotherapy used to prevent perinatal HIV-1 transmission), and had a detectable plasma HIV-1 RNA level, as determined by an optical density у0.2, according to the Roche Amplicor assay (∼400 copies/ mL). Subjects were excluded if they had documented perinatal transmission or transfusion-related transmission of HIV or had received HIV immunotherapy, including HIV vaccines.
HAART was selected by the individual study site clinicians and was required to consist of a minimum of 2 nucleoside reverse-transcriptase inhibitors plus either a protease inhibitor or efavirenz, at standard adult dosages. Sites were encouraged to discuss the importance of adherence to medication before the beginning of therapy and were permitted to use any methods available to assist in adherence.
The study was reviewed yearly by a study monitoring committee composed of team members, 1 PACTG clinician, and 1 Adolescent Trials Network clinician who was not on the protocol team. At the first review, because of the lower than anticipated virologic success rate, the sample size was increased from the original 80 patients to 120.
Schedule of evaluations. Subjects were assessed at baseline, days 1 and/or 2, 4, 7, 10, 14, and 21, and weeks 4, 8, 12, 16, and 24. Plasma obtained from subjects at each visit was used for the quantitation of HIV RNA. At baseline and weeks 4, 8, 12, 16 , and 24, subjects had an interim medical history, physical examination, complete blood count, and blood chemistry panel. An adherence self-report developed by the PACTG that records the number of doses of each medication that were reported to have been missed during the preceding 3 days was also administered at these visits [20] . The subjects also had a lymphocyte subset flow-cytometric panel completed at local PACTG-certified immunology laboratories, which included the enumeration of CD4 and CD8 cells.
At baseline and weeks 12 and 24, blood samples were obtained for expanded 3-color flow cytometry panel and lymphocyte proliferation assays (LPAs). Subjects were also assessed for delayed-type hypersensitivity (DTH) by skin testing at baseline and week 12. DTH skin testing was performed using Candin (ALK Laboratories; 0.1 mL injected intradermally and interpreted 48 h later), according to the technique described by the Centers for Disease Control and Prevention (CDC). Induration у2 mm was considered to be a positive response.
Assessment of virologic outcome. Subjects were categorized as having either a "virologic success" or "virologic failure" on the basis of their virus load measurements. Virologic success was defined as an OD !0.2, according to Roche Amplicor testing, at weeks 12 and 16 or at least a 1-log decline from baseline at week 12, followed by an OD !0.2 at weeks 16 and 24. All other virus load responses were considered to be virologic failures. If virus load data were unavailable at either week 12 or 16 from an individual subject, the virus load at week 24 was used, or, if data from week 24 were also missing, those from week 8 were used to determine virologic success or failure.
Laboratory data. Plasma samples were assayed for HIV-1 RNA by use of the Roche AMPLICOR HIV-1 Monitor test in PACTG-certified virology laboratories [21, 22] . Detailed 3-color flow-cytometric assays were performed at PACTG pediatric immunology core laboratories, by use of the following markers: CD4 62L/45RA, CD8 62L/45RA, CD8 38/DR, CD4 95/28, CD8 95/28, CD4 45RO/45RA, and CD8 45RO/45RA [11, 23] . LPAs were performed as described elsewhere [24] , by use of pokeweed mitogen (10 mg/mL; Sigma), Candida (10 and 50 mg/mL; Greer Laboratories), and tetanus (1.25 and 2.5 mg/mL; Connaught) antigens. LPA responses were evaluated as stimulation indices (SIs), with subjects who had an SI 13 for Candida and tetanus and SI 15 for pokeweed mitogen being classified as responders.
Statistical analysis. Categorical variables were compared by use of either x 2 or Fisher's exact tests. Paired comparisons were done using McNemar's test. Logistic regression was used to determine whether immunologic variables at baseline predicted virologic outcome, controlling for virus load at study entry. Wilcoxon signed rank tests were used to assess whether changes from baseline in continuous parameters were significantly different from zero. Wilcoxon rank sum tests were used to compare continuous outcomes between groups, defined by virologic success and adherence. A Wei-Johnson test [25] was used to compare changes from baseline across all study weeks between subjects with success versus failure.
RESULTS
Baseline characteristics.
Between March 1999 and October 2001, 121 subjects were enrolled in the study, and 120 began a study-defined HAART regimen. One subject withdrew before starting HAART and was not considered further. The subject characteristics are shown in table 1.
Although the HAART regimen was not specified by the protocol, there were 2 predominant regimens selected for subjects: zidovudine and lamivudine with nelfinavir (nelfinavir regimen;
) and zidovudine and lamivudine with efavirenz (efavin p 44 renz regimen;
). Only the 2 most-common regimens were n p 57 included in the therapy-related analyses. No differences in baseline absolute CD4 cell count ( ) or percentage ( ) P p .54 P p .29 or HIV-1 RNA level at study entry ( ) were found between P p .11 the 2 groups. It appeared that the choice of regimen was a function of clinician preference at a participating site, rather than a subject's baseline characteristics (data not shown).
Adherence. Our outcome variable for these analyses was "complete" adherence through 24 weeks of therapy-we classified subjects as having complete adherence if they appeared for all study visits and reported taking all medications for the 3 days preceding each visit. All other subjects were considered to be "incompletely" adherent. The overall rate of complete adherence up to 24 weeks, regardless of treatment regimen, was 32 (27%) of 120. Baseline HIV-1 RNA, CD4 cell counts and percentage, CDC disease class, sex, and race/ethnicity were found to have no significant association with adherence. However, subjects with complete adherence were slightly older (mean age, 19.4 years) than subjects with incomplete adherence (mean age, 18.5 years;
, Wilcoxon rank sum test). Among subjects who received P p .04 the nelfinavir regimen, 36% reported complete adherence over the course of the 24 weeks of study, compared with only 23% of those who received the efavirenz regimen. This difference was not statistically significant, with or without adjustment for baseline HIV-1 RNA.
Virologic outcome. Of the 120 subjects who began HAART regimens, 111 subjects remained in the study at week 16. Of the 9 subjects who were not evaluable for virologic success, 1 subject died at week 1 from complications of Pneumocystis pneumonia, 1 subject was incarcerated, and 7 refused further participation. All 9 subjects were classified as having virologic failure. Of the remaining 111 subjects, there were 69 subjects who achieved virologic success and 40 who had virologic failure; 2 subjects were lacking sufficient data to determine the virologic outcome. The overall percentage of subjects classified as having a virologic success was therefore 69 (59%) of 118 (95% confidence interval [CI], 49%-68%). Median log 10 levels of HIV-1 RNA copies/mL, by virologic outcome, are shown in figure 1. The virologic success rate decreased with increasing baseline HIV-1 RNA level, with 73% of subjects with HIV-1 RNA !10,000 copies/mL, 58% of those with HIV-1 RNA 10,000-30,000 copies/mL, and 51% of those with HIV-1 RNA 130,000 copies/mL having virologic success, but this trend was not statistically significant.
Virologic outcome was assessed according to initial HAART regimen. This analysis was limited to subjects who had sufficient data to determine a virologic outcome and who had received the 2 most-common HAART regimens. Sixty-seven percent (38/57 subjects) who received the efavirenz regimen and 51% (22/43 subjects) who received the nelfinavir regimen had virologic success ( ). Because we did not use a randomized treatment P p .15 assignment, this result needs to be interpreted with care.
In general, treatment regimens were well tolerated. There were 19 subjects who reported a temporary hold or change in medications due to adverse reactions. These included allergic reactions in 12 subjects, nausea and vomiting in 5, and 1 each of anemia, neutropenia, and neurologic changes. One subject reported both an allergic reaction and nausea and vomiting.
We assessed the relationship between adherence through 16 weeks and virologic outcome in 2 ways. Of the 69 subjects who had virologic success, 31 (45%) reported complete adherence through week 16 (no missed doses during the previous 3 days at weeks 4, 8, 12, and 16), compared with 8 (16%) of 49 subjects who had virologic failure ( ). We also compared the P ! .001 percentage of subjects with no missed doses at each visit (weeks 4 -16), using a Wei-Johnson test, which also showed that subjects with virologic success were more likely to have had complete adherence during weeks 4-16 ( ). P ! .001 Immunologic observations. The median changes from baseline through week 24 for CD4 and CD8 cell counts and percentages for the entire group are shown in table 2. Median CD4 At baseline, only 57 (52%) of 109 subjects demonstrated DTH to Candida. There was no improvement in the percentage of subjects who demonstrated DTH between baseline and week 12 ( ), although data were only available at both time points P p .53 for 76 subjects. Only 12 subjects who were nonresponders to DTH at baseline had a positive skin-test result at week 12.
Immunologic changes in subjects with virologic success and failure. We compared immunologic changes to week 24 between subjects who achieved virologic success and those who did not. Those with virologic success had statistically significant ( ) changes in CD8 and CD4 cell counts and percentages, P ! .01 as shown in table 4. When comparing subjects with virologic success and those with virologic failure over the course of the first 24 weeks, those with success demonstrated significantly greater increases in total CD4 cell count and percentage and significantly greater decreases in CD8 cell count and percentage (table 4) . Subjects with virologic failure, however, also demonstrated significant improvements in CD4 cell count and CD4 and CD8 cell percentages ( for all), demonstrating sig-P ! .03 nificant improvement in immunologic parameters even in the face of incomplete control of viral replication.
Three-color lymphocyte flow-cytometric findings are also summarized in table 4. Subjects with virologic success demonstrated statistically significant increases to week 24 in all absolute numbers of CD4 cells but not in percentages. In comparison, significant increases in absolute numbers of CD4 naive and memory cells were demonstrated in subjects with virologic failure. When subjects with virologic success were compared with those who had virologic failure, significantly larger increases in the subjects with virologic success were demonstrated for CD4 naive and memory cells.
Subjects with virologic success demonstrated statistically significant reductions in activated and memory CD8 cell counts and percentages over the course of the first 24 weeks (table 4). They also had increases in the percentage, but not the absolute numbers, of CD8 naive cells. In comparison, no significant changes in CD8 naive or memory populations occurred in subjects who had virologic failure. When subjects with virologic success and those with virologic failure were compared over the course of the first 24 weeks, those with virologic success demonstrated significantly larger reductions in the percentage and absolute number of activated and memory CD8 cells.
Finally, we compared changes in LPA by virologic outcome. There were no statistically significant differences between virologic-outcome groups. In general, the percentage of subjects with positive responses was greater in subjects with virologic success, compared with failure, for all antigens tested at 24 weeks. There was also no evidence of an increased percentage of subjects demonstrating DTH by skin testing at week 12 in subjects with virologic success, compared with those who had virologic failure. Among those with virologic failure ( ), n p 25 11 subjects had negative DTH at baseline; 3 of these had a positive response at week 12. Of subjects with virologic success ( ), 25 subjects had negative DTH at baseline. Of these, n p 49 9 had positive DTH at week 12.
Immunologic status at baseline as a predictor of virologic outcome. To determine whether any baseline immunologic characteristics were predictive of virologic success, each immunologic measure (including basic and 3-color flow, LPA, and DTH measurements) at baseline was included as a continuous independent predictor in separate logistic regressions, with virologic outcome as the dependent variable. All models were adjusted for baseline HIV-1 RNA on a log 10 scale. No immunologic parameters at baseline were significantly predictive of virologic response.
Sex-related findings. We compared baseline virologic and immunologic characteristics of our cohort by sex. When virus loads at baseline were grouped as !10,000, 10,000-30,000, and 130,000 copies/mL, there was a trend toward higher virus loads in males, compared with females ( ). If virus load was P p .059 compared as a continuous variable, similar findings were observed (
). There were no sex-related differences in P p .053 baseline CD4 or CD8 values or in any 3-color flow-cytometric measurements.
We also assessed virologic outcome by sex and were unable to demonstrate any differences ( ). Of 60 females, 27 P p .46 (45%) achieved virologic success, compared with 22 (38%) of 58 males.
DISCUSSION
To our knowledge, this is the first study that specifically addresses the response to HAART in HIV-1-infected adolescents. Overall, the response to HAART was less than had been predicted on the basis of study results for treatment-naive adults. In the present study, 59% (95% CI, 49%-68%) of the subjects met the study definition of virologic success. In comparison, multiple studies in adults have shown that 190% of participants suppress viral replication with similar drug regimens [1] [2] [3] [4] . We were unable to link the response to therapy to any baseline characteristics of the subject, including virus load at baseline. We did, however, link virologic success with adherence to medication as determined by self-report. Taken together with the rising numbers of HIV-infected adolescents [7] and the demonstration of poor adherence to medications in other studies [8, 9] , this observation underscores the difficulty in managing HIV-infected adolescents. Clearly, additional efforts to improve adherence to medication in this population will be needed. Our study was implemented before the most-recent public health guidelines regarding the timing of the beginning of drug therapy [26] . On the basis of those recommendations, only 65 of 120 subjects had a virus load (155,000 copies/mL) or CD4 cell count or percentage (!350 cells/mL or !15%) that would indicate the necessity to begin therapy. Of the 65, 33 (51%) had virologic success, compared with 68% of those who did not meet the recommendations for starting therapy ( ). P p .064 Bearing in mind that the choice of HAART regimen in our subjects was not determined by randomization but by the choice of the local clinician, subjects treated with a regimen that contained nelfinavir responded as well as those who received a regimen that contained efavirenz. Of interest, there was also no difference in adherence between the regimens. This was surprising, because we had anticipated the pill burden to affect adherence. This was not seen in our population-36% of subjects who received the nelfinavir regimen during the study period reported complete adherence over the course of 24 weeks, compared with only 23% of those who received the efavirenz regimen.
Immunologic responses to therapy, including increases in both CD4 cell count and percentage, as well as decreases in CD8 cell counts and percentages, were seen through the 24 weeks of the study. The increases in absolute CD4 cell count and percentage were similar to those observed in both adults [27] [28] [29] and children treated with HAART [30, 31] . Differences between these HAART-treated populations, however, are demonstrated in changes in the absolute CD8 cell count. We saw a statistically significant reduction in absolute CD8 cell counts. In comparison, Lederman et al. [28] observed an increase in absolute CD8 cell counts at week 12 in their population of adults with advanced disease. However, other studies of adults [27, 31, 32] and children [24, 30] have shown either decreases or no change in CD8 cell counts, which suggests that other factors, including baseline immunosuppression, may affect CD8 responses.
We observed statistically significant increases in the absolute number of CD4 naive and memory cells in our population. These changes are similar to those of other studies of adults and children [24, 27, 30, 32, 33] . Thus, regardless of the population studied, HAART is associated with increases in the number of CD4 naive and memory cells. Even though we demonstrated the capacity for expansion of CD4 naive lymphocytes in our adolescents, the value attained after 24 weeks of HAART was lower than that predicted for HIV-uninfected adolescents [34] . Furthermore, the functional capability of these cell populations, with respect to HIV-specific immunity, is not known.
There were also significant reductions in absolute numbers and percentages of activated and memory CD8 cells, similar to data reported in other adult and pediatric studies [24, 27, 29] . These data are consistent with prior observations of increased proliferation, as measured by the Ki67 antigen [12] .
There was no observed change in the absolute numbers of CD8 naive cells; however, an increase in the percentage of the CD8 naive subset was statistically significant. An increased number of CD8 naive cells in the HIV-infected adolescent population, in comparison to adults, was previously demonstrated in the Reaching for Excellence in Adolescent Care and Health cohort, a large prospective cohort of HIV-infected and -uninfected youth [11] . The higher baseline CD8 naive cell count found in our adolescent population may reflect enhanced thymic capacity and a greater ability to generate naive lymphocytes than in adults [11] . These high numbers of naive CD8 cells persisted through week 24, which suggests that this cell population persists even with antiretroviral therapy.
We were unable to demonstrate improved responses after HAART by use of LPA. In contrast, adults with advanced disease who were enrolled in AACTG 315 demonstrated improvement in Candida antigen at weeks 12 and 24. [28, 33] . Our failure to show improvement at week 12 may have been related to the baseline differences in our populations. Observations in children (ages 2-17 years) [24] and adults with less viral suppression [29] are consistent with our findings. Similar to other studies, we were unable to demonstrate a difference in DTH skin testing. These findings are most likely the consequence of relatively intact cellmedicated immunity and DTH in our population [10] .
An important feature of our study was the immunologic response among subjects classified as virologic failures. Improvements in immune function occurred even in the presence of ongoing viral replication. This observation may reflect a robust capacity of the immune system of adolescents to respond to antiretroviral therapy, even in the absence of control of viral replication. These findings are consistent with prior reports of patients with virus strains that are resistant to multiple treatments maintaining their immune status while receiving ineffective agents, in comparison to rapid immune deterioration when therapy was stopped [35] [36] [37] [38] . Although improvements in the number of CD4 cells were evident, there were no significant changes in CD8 populations in subjects who had virologic failure. This is especially important because no reduc- tion in activated CD8 cells was demonstrated, and these cells are linked with the progression of HIV disease [35, 39] . A continued increase in activated CD8 cells in subjects with virologic failure, even while they are receiving HAART, may predict a greater loss of CD4 cells over time [39] . Longer followup of this cohort will provide more information on the decrease in CD4 cell counts in subjects with virologic failure.
We were unable to identify any factor-including age, sex, race/ethnicity, or virus load-at baseline that predicted a successful virologic outcome. It should be noted that our population was relatively immunologically robust, as indicated by the high baseline CD4 count (median count, 400 cells/mL 3 ). Whether baseline characteristics would influence outcome in a group of patients with more advanced disease cannot be determined from these data. The only factor that influenced virologic outcome was adherence to medication. Our measurement of adherence was incomplete: we relied solely on selfreport. Furthermore, we only analyzed subjects who reported never missing a dose of medication, compared with those who missed any number of doses. Further investigation to determine the degree of adherence necessary to achieve a virologic response is ongoing.
Another important feature of our cohort is the approximately equal distribution of males and females. Balance by sex in HIV clinical trials is usually not achieved. Because of this, we investigated sex-related differences in the response to HAART in our population, but we were unable to find striking differences. Although no comparison reached statistical significance, males appeared to have higher virus loads at baseline. Thus, similar to findings in adults, females demonstrated a trend toward lower virus loads despite comparable CD4 cell counts [40, 41] . This finding reinforces the importance of considering sex as a variable in the analysis of clinical trial data.
Our results demonstrate that HIV-1-infected adolescents have a less successful virologic response to HAART than adults. However, even in subjects who did not have a virologic response, improvements in absolute CD4 cell counts were seen. We did not demonstrate reductions in activated CD8 cell counts in those subjects who did not achieve virologic suppression, which suggests that the improvement in numbers of CD4 cells would not be sustained in subjects with virologic failure. Adherence to medication was the only factor that predicted the control of viral replication. Additional focus on improving adherence to medication in adolescents will be critical in realizing the same benefits of HAART that have been demonstrated in adults. Subjects on our study continue to be monitored, and the data will provide more information on long-term virologic and immunologic responses to HAART. This will provide important information about the durability of virologic control and improvements in immunologic parameters in adolescents.
